Discover What Complete Single-Cell Truth Reveals

     

BioSkryb Genomics delivers high-fidelity single-cell data that reveals biology at unprecedented resolution. Our patented whole genome amplification technology, primary template-directed amplification (PTA) that achieves 97% genome coverage, is combined with full-length transcriptome and surface protein analysis from individual cells in a unified, single-day, automation-compatible workflow. This complete genotype-to-phenotype view enables breakthrough discoveries in research and therapeutic development, powers next-generation diagnostics, and generates clinical-grade datasets that advance the next generation of AI-driven precision medicine.

INTEGRATED SINGLE-CELL MULTIOMICS – BIOSKRYB DELIVERS THE COMPLETE BIOLOGICAL PICTURE

     

The BioSkryb Platform: Driving Discoveries That Define Future Therapies and Diagnostics

As the field moves beyond bulk sequencing's inability to resolve cellular heterogeneity, researchers use BioSkryb technologies to amplify and analyze the genomes and transcriptomes of individual cells. A uniquely integrated platform delivering unified DNA and RNA from single cells with whole-genome coverage, BioSkryb reveals rare mutations and cell populations that bulk methods average away and partitioning methods cannot fully resolve. Explore how investigators are using our products, including ResolveDNA® and ResolveOME™ kits and BaseJumper® bioinformatics platform, in high impact oncology, neurology, and discovery research publications.

     

Accelerating Translational Research and Clinical Development

Biopharma teams use the BioSkryb multiomic product portfolio to extract deeper insight from limited samples across translational research and clinical development programs. Our platform extracts maximum biological insight from precious samples while generating the deep multiomic datasets required for AI-driven biomarker discovery. With our partners, we are developing formalin fixed, paraffin embedded (FFPE) multiomic solutions to unlock archived tissue repositories and rescue clinical trial samples that fail with other technologies. In hematologic malignancies, collaborators are advancing next-generation measurable residual disease (MRD) approaches that more fully characterize residual disease cells to support informed therapy selection and precision cancer care. Discover how BioSkryb can accelerate your programs.

     

Solving the Diagnostics "Quantity Not Sufficient" Crisis

Femtogram-scale sensitivity helps recover valuable data from samples labeled “quantity not sufficient” (QNS), which can account for up to 30% of cases in high-volume workflows. Diagnostic partners use BioSkryb technology to analyze fine-needle aspirates (FNA) and archival samples, enabling analysis of ultra-low input samples. Explore diagnostic partnership opportunities.

     

Generating Complete Data for AI-Driven Medicine

Biopharma and artificial intelligence (AI) companies require comprehensive multiomic data and high-fidelity datasets to train predictive models and discover novel biomarkers. Current approaches rely on bulk sequencing that averages cellular heterogeneity or single-cell methods limited to RNA end-counting. BioSkryb generates complete single-cell multiomics—genome, full-length transcriptome, and surface proteins—the complete biological data required to develop AI models that identify new clinically actionable targets and biomarkers. Inquire about AI dataset partnerships.